Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 26;13(17):5050.
doi: 10.3390/jcm13175050.

Sphingolipids and Chronic Kidney Disease

Affiliations
Review

Sphingolipids and Chronic Kidney Disease

Zrinka Šakić et al. J Clin Med. .

Abstract

Sphingolipids (SLs) are bioactive signaling molecules essential for various cellular processes, including cell survival, proliferation, migration, and apoptosis. Key SLs such as ceramides, sphingosine, and their phosphorylated forms play critical roles in cellular integrity. Dysregulation of SL levels is implicated in numerous diseases, notably chronic kidney disease (CKD). This review focuses on the role of SLs in CKD, highlighting their potential as biomarkers for early detection and prognosis. SLs maintain renal function by modulating the glomerular filtration barrier, primarily through the activity of podocytes. An imbalance in SLs can lead to podocyte damage, contributing to CKD progression. SL metabolism involves complex enzyme-catalyzed pathways, with ceramide serving as a central molecule in de novo and salvage pathways. Ceramides induce apoptosis and are implicated in oxidative stress and inflammation, while sphingosine-1-phosphate (S1P) promotes cell survival and vascular health. Studies have shown that SL metabolism disorders are linked to CKD progression, diabetic kidney disease, and glomerular diseases. Targeting SL pathways could offer novel therapeutic approaches for CKD. This review synthesizes recent research on SL signaling regulation in kidney diseases, emphasizing the importance of maintaining SL balance for renal health and the potential therapeutic benefits of modulating SL pathways.

Keywords: ceramides; chronic kidney disease; sphingolipids; sphinogosine-1-phosphate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Sphingolipid synthesis pathways, created with Biorender.com. Note: various enzymes involved in the formation of complex sphingolipids are not presented here.

Similar articles

References

    1. Hannun Y.A., Obeid L.M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 2018;19:175–191. doi: 10.1038/nrm.2017.107. - DOI - PMC - PubMed
    1. Kumar M., Dev S., Khalid M.U., Siddenthi S.M., Noman M., John C., Mohamad T. The Bidirectional Link Between Diabetes and Kidney Disease: Mechanisms and Management. Cureus. 2023;15:e45615. doi: 10.7759/cureus.45615. - DOI - PMC - PubMed
    1. Woo C.Y., Baek J.Y., Kim A.R., Hong C.H., Yoon J.E., Kim H.S., Koh E.H. Inhibition of Ceramide Accumulation in Podocytes by Myriocin Prevents Diabetic Nephropathy. Diabetes Metab. J. 2020;44:581–591. doi: 10.4093/dmj.2019.0063. - DOI - PMC - PubMed
    1. Kaabia Z., Poirier J., Moughaizel M., Aguesse A., Billon-Crossouard S., Fall F., Durand M., Dagher E., Krempf M., Croyal M. Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species. Sci. Rep. 2018;8:15893. doi: 10.1038/s41598-018-34329-3. - DOI - PMC - PubMed
    1. Pruett S.T., Bushnev A., Hagedorn K., Adiga M., Haynes C.A., Sullards M.C., Liotta D.C., Merrill A.H.J. Biodiversity of sphingoid bases (“sphingosines”) and related amino alcohols. J. Lipid Res. 2008;49:1621–1639. doi: 10.1194/jlr.R800012-JLR200. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources